NCT02795858 2025-02-19A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid TumorsDana-Farber Cancer InstitutePhase 2 Completed43 enrolled 11 charts
NCT00781911 2019-09-20A Study of Cixutumumab (IMC-A12) in Islet Cell CancerEli Lilly and CompanyPhase 2 Completed43 enrolled 12 charts